A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

Summary

This study will test the safety and activity of SGN-CD48A in patients with multiple myeloma. SGN-CD48A will be given on Days 1, 8, and 15 of a 28-day cycle. Prior to protocol amendment 2, SGN-CD48A was given every 3 weeks.

Timeline

Start

2018-02-20

Primary completion

2019-08-23

Completion

2019-08-23

Outcome

Outcome not reported

Stopped: “Due to overall benefit/risk profile”

Drugs

Indications